Hard To Treat Diseases (HTDS) Pending Merger Update
CLEARWATER, FL, Jan. 2 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS) www.htdsmedical.com Further to the company's news release of December 30, 2008 where amongst other things the company addressed the targeted merger candidate, firstly the company is pleased to announce that it has appointed its new Chief Science Consultant.
The director of research and business development for the company is Andrea Zecevic Rubio. Andrea is a University of Toronto graduate specializing in the field of Microbiology. Andrea has worked for Pasteur Meriuex Connaught Laboratories (Now Aventis) for several years as a microbiologist, before starting her own consulting business in the field of medical research, and software developments in non medical fields. Andrea is fluent in several languages, such as Spanish, Italian, Portuguese, and English which the company will draw upon with International clients.
Andrea's mandate with HTDS is to research target merger companies in the medical sector that have great potential in bringing valuable products that can make a difference into the market and merging them with HTDS. In addition, Andrea's tasks will include consulting the HTDS management and board directors on the validity of medical operations in the capacity of scientific areas only.
Andrea has identified a suitable merger operating candidate. The merger candidate is a China based bio chemical company.
Andrea said "Currently we have sent two company representatives to examine a company in China that is currently the leading and the largest manufacturer and exporter of vaccines in China offering Hepatitis A Vaccine, Rabies Virus Vaccine, Influenza Virus Vaccine, Polio Vaccine, along with some pharmaceutical raw materials.
In addition, we have entered into a contract with several European companies that are currently at various stages of product launching, from a successful clinical trials stage, to a ready to launch product stage.
The European companies we have examined are currently focused on the chemical repair of damage to the CNS (central nervous system), MS (Multiple Sclerosis) SARS, Hepatitis C, HIV through the enhancement of already approved drugs such as "Virazole" and Tiazofurin.
We also have serious interest in a product that utilizes a natural human body defense from foreign substances as microorganisms, tumors, and antigenes. Beside antiviral effects, the product plays an important role in the battle against various tumors and diabetes."
For scientific dialogue and inquiry only Andrea can be reached via e mail at azconsulting2001@gmail.com. For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com.
In other corporate updates, the company has completed a filing on Pink Sheets re China Medical company. This is a scrubbed version (relevant merger company named removed) until the transaction is closed. The company will post the East European merger candidate shortly.
The company will provide further details as they become available.
Safe Harbor statement under the Private Securities Litigation Reform Act of 1995: Certain information contained in this release contains forward-looking statements that involve risk and uncertainties, including but not limited to, those relating to development and expansion activities, domestic and global conditions, and market competition.
For scientific dialogue and inquiry only Andrea can be reached via e-mail at azconsulting2001@gmail.com. For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com
CONTACT: For scientific dialogue and inquiry only Andrea can be reached via e-mail at azconsulting2001@gmail.com. For any corporate matters the readers should contact the company directly at corporate@htdsmedical.com
